Menu
Recruiting NCT05436093

CLDN18.2 Targeting Nanobody Probe for PET Imaging in Solid Tumors

No phase Interventional Solid Tumor

For patients and families

In plain language

An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.

What is being studied
The protocol lists: 18F-FDG.
Who it may be relevant to
Registry conditions: Solid Tumor. Basic parameters: 18 years — 75 years · All.
What needs checking
Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
Where it takes place
China
Next step
Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →

Unsure about the terms? Read our patient guide →

Overview

The objective of the study is to construct a noninvasive approach 68Ga-ACN376 PET/CT to detect the CLDN18.2 expression of tumor lesions in patients with Solid tumors and to identify patients benefiting from CLDN18.2 targeting treatment.

Interventions

  • Drug 18F-FDG
    All study participants will undergo one 18F-FDG PET/CT scan.

Primary outcome measures

  • Standardized uptake value（SUV） [Time frame: 2 years]

Eligibility criteria

Inclusion criteria

  • 1\. Aged >18 years old; ECOG 0 or 1;
  • 2\. Patients with solid tumors;
  • 3\. Has at least one measurable target lesion according to Response Evaluation Criteria in Solid Tumors (RECIST V1.1);
  • 4\. life expectancy >=12 weeks.

Exclusion criteria

  • 1\. Significant hepatic or renal dysfunction;
  • 2\. Is pregnant or ready to pregnant;
  • 3\. Cannot keep their states for half an hour;
  • 4\. Refusal to join the clinical study;
  • 5\. Suffering from claustrophobia or other mental diseases;
  • 6\. Any other situation that researchers think it is not suitable to participate in the experiment.

Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.

Healthy volunteers: No

Study design

Allocation
N/A
Model
Single group
Masking
Open label
Primary purpose
Screening

Study locations

China · 1 center
  • Beijing cancer hospital — Beijing

Identifiers

NCT: NCT05436093 · 2022KT96

Primary sources (government registries)

View this study on ClinicalTrials.gov ↗